This application proposes the addition of a Neuroimaging Core (NIC) to the newly established Alzheimer?s Disease Core Center (ADCC) at Wake Forest School of Medicine. The NIC will address a critical need to establish biomarkers that reliably differentiate Alzheimer?s disease (AD) from other conditions that affect cognition in aging. Recently, an AD research framework was developed for a biologically-based classification to enhance identification of disease mechanisms, to appropriately target therapeutic interventions, and to track therapeutic response and disease progression. Neuroimaging techniques, such as magnetic resonance imaging (MRI) to measure structural changes and positron emission tomography (PET) to track changes in pathological hallmarks such as b-amyloid and tau, comprise a powerful approach to characterize the progressive pathology associated with cognitive decline and to differentiate AD from other dementias. To establish reliable biomarkers associated with AD and other conditions that impair cognition with aging will require a large collaborative effort and the national NIH ADC network is ideally suited to address this need. The Wake Forest ADCC can make unique contributions to the network; the NIC will conduct longitudinal, multimodal neuroimaging paired with phenotypic and genomic characterization of a diverse cohort of participants. The NIC will provide expertise and resources to complement the ADCC themes, which focus on: 1) early transitions from normal aging to mild cognitive impairment (MCI) and AD; 2) the role of metabolic and vascular risk in these transitions; and 3) ethnic differences modulating these relationships.
The first aim of the NIC will be to leverage existing Clinical Core and imaging infrastructure, including research-dedicated PET and MRI, cyclotron, and advanced analytic pipelines to help identify the causes of AD and develop novel strategies for prevention and treatment. As a second aim, the NIC will optimize participation of underrepresented groups in neuroimaging protocols, with a special focus on African-Americans, to better understand and reduce disparities in their risk of AD and other dementias.
The third aim will be to expand interactions with the ADC network and NACC, and with institutional partners through aligned neuroimaging methods and new collaborations.
The final aim will be to provide training and consultation on the latest scientific advances in neuroimaging to ADCC-affiliated investigators. Through these aims, the Wake Forest ADCC NIC will further the understanding of AD pathology and its relationship to cognitive decline and will significantly enhance the Center?s contribution to the ADC network and to investigators worldwide.

Public Health Relevance

This application proposes the addition of a new Neuroimaging Core to the Wake Forest Alzheimer?s Disease Core Center (ADCC). Establishment of this Neuroimaging Core will enable long-term, repeated observation of the pathological changes associated with cognitive decline in Alzheimer?s disease using multiple neuroimaging techniques in well-characterized study participants. The Neuroimaging Core will help Wake Forest ADCC researchers differentiate AD from other dementias and address important scientific questions, such as the contributions of vascular and metabolic risk factors in multiple ethnic groups, and will greatly expand the resources that are provided by the ADCC to the broader Alzheimer?s disease research field. !

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
3P30AG049638-04S1
Application #
9705333
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
2016-09-01
Project End
2021-06-30
Budget Start
2019-08-01
Budget End
2020-06-30
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Espeland, Mark A; Chen, Jiu-Chiuan; Weitlauf, Julie et al. (2018) Trajectories of Relative Performance with 2 Measures of Global Cognitive Function. J Am Geriatr Soc 66:1575-1580
Casanova, Ramon; Barnard, Ryan T; Gaussoin, Sarah A et al. (2018) Using high-dimensional machine learning methods to estimate an anatomical risk factor for Alzheimer's disease across imaging databases. Neuroimage 183:401-411
Nagpal, Ravinder; Wang, Shaohua; Solberg Woods, Leah C et al. (2018) Comparative Microbiome Signatures and Short-Chain Fatty Acids in Mouse, Rat, Non-human Primate, and Human Feces. Front Microbiol 9:2897
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Espeland, Mark A; Luchsinger, Jose A; Neiberg, Rebecca H et al. (2018) Long Term Effect of Intensive Lifestyle Intervention on Cerebral Blood Flow. J Am Geriatr Soc 66:120-126
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 34 publications